Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
WJMSC-P01 Wharton’s Jelly MSCs in Type 1 Diabetes in Children and Adolescents
2024-518270-14-00Phase 2Authorised
- Sponsor
- Region Uppsala
- Start
- Nov 2024
- Modality
- Stem Cell Therapies → Cell Therapies
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in diabetes mellitus type 1 (T1D) comparing ProTrans (WJMSC) with Placebo (2 arms). Primary endpoints: Safety (adverse events) and Change in C-peptide AUC (0–120 min) during MMTT at 12 months. Planned start Nov 2024; status: authorised.
02
Drugs
ProTrans
03
Conditions
diabetes mellitus type 1 (T1D)
Beyond the preview
Go deeper on 2024-518270-14-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-518270-14-00.